FULVESTRANT

Stage IV Uterine Corpus Cancer AJCC v8

Pamela MunsterSmall moleculePhase 1Dormant

CC

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 95/ 100

Competitive context

49 Active assets in the Stage IV Uterine Corpus Cancer AJCC v8 cohort.

Asset / Sponsor	Phase	Rating
Carboplatin City of Hope Medical Center	Phase 3	BB
Irinotecan M.D. Anderson Cancer Center	Phase 2	BB
Bms-907351 M.D. Anderson Cancer Center	Phase 2	BB
Nivolumab M.D. Anderson Cancer Center	Phase 2	B
Tak-228 National Cancer Institute (NCI)	Phase 2	B

View all 50 →

Same molecule, other indications

FULVESTRANT is also rated in:

Hormone Receptor Positive TumorDormant

BB

Indicative ·

70 / 100

hormone receptor-positive breast cancerDormant

BB

Indicative ·

70 / 100

Progesterone Receptor PositiveDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.